Idaho Independent Bank Announces 2017 Second Quarter and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
33
Idaho Independent Bank Announces 2017 Second Quarter and Year-to-Date Results

COEUR D’ALENE, Idaho, July 13, 2017 (GLOBE NEWSWIRE) -- Jack W. Gustavel, Chairman and Chief Executive Officer of Idaho Independent Bank (“IIB” or the “Bank”) (OTC Pink:IIBK), announced IIB’s unaudited, consolidated financial results for the second quarter and year-to-date ending June 30, 2017. 

Pre-tax income for the second quarter was $1.9 million, an increase of 58% over the $1.2 million earned in the second quarter of 2016.  Net income after taxes for 2017 was $1.2 million, or $0.15 per diluted share, compared to $1.1 million, or $0.13 per diluted share, for the second quarter of 2016.  “Pre-tax income was helped by strong loan and deposit growth and an increase in the Bank’s net interest margin,” Mr. Gustavel said.  Income tax expense for the 2016 quarter included a $294,000 benefit related to a reversal of the Bank’s deferred tax valuation allowance, while there was no reversal in 2017. After-tax income for the six months ended June 30, 2017, was $2.0 million, or $0.25 per diluted share, compared to $1.8 million, or $0.23 per diluted share, for 2016.  The 2016 income tax expense was reduced by a valuation allowance reversal that totaled $513,000, while there was no reversal in 2017.

At June 30, 2017, the Bank's total assets were $661.4 million, an increase of $70.6 million, or 11.9%, when compared to June 30, 2016.  Total loans, including loans held-for-sale, increased $42.0 million, or 13.5%, to $354.0 million; while deposits and repurchase agreements increased $66.7 million, or 13.0%, to $578.2 million over the same timeframe.  As of June 30, 2017, the allowance for loan and lease losses was $6.3 million, or 1.8% of total loans, excluding loans held-for-sale, and nonperforming assets were less than 0.2% of total assets.

As of quarter end, the Bank’s stockholders' equity to average total assets was 10.0%, and its capital ratios exceeded the regulatory thresholds required to be considered “Well-Capitalized.”  During the quarter, the Bank purchased 70,617 shares of its common stock at a cost of $684,293.  IIB may still purchase shares worth up to $1.4 million under its current buyback approval.  

IIB will file its Consolidated Report of Condition and Income for the quarter ended June 30, 2017, ("Call Report") with the Federal Deposit Insurance Corporation by July 30, 2017.  The Call Report will be posted on the Federal Financial Institutions Examinations Council website at http://cdr.ffiec.gov/public/ .

About IIB

IIB was established in 1993 as an Idaho state-chartered, commercial bank that operates branches in Boise (3), Caldwell, Coeur d’Alene, Hayden, Meridian, Mountain Home, Nampa, Star, and Sun Valley/Ketchum, Idaho.  IIB earned honorable mention as one of the Best Places to Work in Idaho through a survey conducted by Populus in 2016 & 2017, was named to DepositAccounts.com’s Top 200 Healthiest Banks in America in 2015 & 2016, and was named among the top 1% most extraordinary banks in the U.S. by The Institute for Extraordinary Banking TM in 2016.  The Bank has approximately 200 employees throughout the State of Idaho. To learn more about IIB, visit us online at www.theidahobank.com .

Statements contained herein concerning future performance, developments or events, expectations for earnings, growth and market forecasts, and similar statements that are not historical facts are intended to be “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, and as such, are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations or our stated objectives. Factors that could cause actual results to differ materially, include, but are not limited to, declines in regional and general economic conditions; changes in interest rates, deposit flows, demand for loans, real estate values, competition, and/or loan delinquency rates; changes in accounting principles, practices, policies, or guidelines; changes in legislation or regulations; changes in the regulatory environment; changes in monetary policy of the Federal Reserve Bank; changes in fiscal policy of the Federal government and the State of Idaho; changes in other economic, competitive, governmental, regulatory, and technological factors affecting operations, pricing, products, and services; material unforeseen changes in the liquidity, results of operations, or financial condition of the Bank's customers .  Accordingly, these factors should be considered in evaluating forward-looking statements, and there should not be undue reliance placed on such statements. The Bank undertakes no responsibility to update or revise any forward-looking statements.

Idaho Independent Bank              
Financial Highlights (unaudited)              
(dollars in thousands, except share data)              
               
  Three Months Ended   Six Months Ended
CONDENSED STATEMENT OF OPERATIONS June 30,   June 30,
    2017       2016       2017       2016  
Net interest income $ 5,515     $ 4,519     $ 10,486     $ 8,829  
Provision for loan losses   -       -       -       -  
Net interest income after provision for loan losses   5,515       4,519       10,486       8,829  
Noninterest income   1,792       2,130       3,567       3,277  
Noninterest expense   5,433       5,438       10,946       10,060  
Income before income tax expense (benefit)   1,874       1,211       3,107       2,046  
Income tax expense (benefit)   684       139       1,134       202  
Net income $ 1,190     $ 1,072     $ 1,973     $ 1,844  
               
Earnings per share:              
Basic $ 0.16     $ 0.13     $ 0.26     $ 0.23  
Diluted $ 0.15     $ 0.13     $ 0.25     $ 0.23  
               
SELECTED BALANCE SHEET ACCOUNTS June 30,   June 30,        
    2017       2016          
Loans held for sale $ 4,903     $ 9,016          
Loans receivable   349,058       303,023          
Gross loans   353,961       312,039          
Allowance for loan losses   6,290       6,293          
Total assets   661,431       590,806          
Deposits   553,527       489,792          
Customer repurchase agreements   24,691       21,660          
Total deposits and repurchase agreements   578,218       511,452          
Stockholders' equity   65,594       65,036          
               
PER SHARE DATA              
Common shares outstanding   7,564,886       7,998,222          
Book value per share $ 8.67     $ 8.13          
               
  Three Months Ended   Six Months Ended
PERFORMANCE RATIOS (annualized) June 30,   June 30,
    2017       2016       2017       2016  
Return on average assets   0.73 %     0.75 %     0.61 %     0.67 %
Return on average equity   7.26 %     6.64 %     6.11 %     6.06 %
Efficiency ratio   74.35 %     81.79 %     77.89 %     83.10 %
Net interest margin   3.63 %     3.46 %     3.52 %     3.42 %
               

CONTACT: Jack W. Gustavel IDAHO INDEPENDENT BANK 1260 W. Riverstone Drive Coeur d’Alene, Idaho 83814 (208) 292-1902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 5

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Flavors of Portugal at the 2025 Port Wine Fest

Updated Category News Views 380

Port Wine Fest: A Celebration of Portuguese Culture The Port Wine Fest is an exciting festival dedicated to showcasing Portuguese wines and cuisine. In 2025, it will embark on its third edition with events scheduled across various vibrant cities, including San Francisco, Chicago, and New York City, creating an unforgettable experience that combines culture, food, and fine...

Continue Reading
Earnings Projections for 5E Advanced Materials to Watch

Updated Category News Views 118

Understanding 5E Advanced Materials’ Earnings Expectations 5E Advanced Materials (NASDAQ: FEAM) is gearing up to unveil its quarterly earnings report soon. Investors are keenly awaiting the details, as quarterly performance can significantly influence stock trends and market sentiment. Projected Earnings per Share Analysts are estimating an earnings per share (EPS) of...

Continue Reading
Verano Launches Adult Cannabis Sales in Connecticut's Waterbury

Updated Category News Views 111

Verano Launches Adult Use Cannabis Sales at Zen Leaf Waterbury Zen Leaf Waterbury has achieved a significant milestone by transitioning its dispensary from medical-only sales to hybrid sales, allowing for adult use cannabis sales in Connecticut. Location and Accessibility of Zen Leaf Waterbury Conveniently located at 237 East Aurora Street in Waterbury, the fifth largest...

Continue Reading
Innovative Medical Education Suite Introduced by Treatment.com AI

Updated Category News Views 176

Revolutionizing Medical Education with AI Integration Treatment.com AI Inc. is making strides in medical education by unveiling a cutting-edge platform designed to enhance clinical skills training. This innovation aims to provide a more immersive and effective educational experience for medical students. The newly launched Medical Education Suite (MES) represents a...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 24

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading